摘要
甲状腺癌是内分泌系统常见肿瘤,其发病机制尚未完全研究清楚。近年来关于激活蛋白-1(activator protein-1,AP-1)与甲状腺癌相关研究逐渐增多,BRAF、RET、RAS等基因突变及细胞因子、多肽激素等多种因素激活MAPK信号通路,促进Fos、Jun等基因转录,增加AP-1表达。AP-1在甲状腺癌中过表达可激活下游靶基因如VEGF、MMP-9、Cyclin D1、Fas等,在甲状腺癌增殖转化、侵袭转移及凋亡治疗过程中发挥重要作用。本文就AP-1与甲状腺癌相关研究进展进行概述。
Thyroid cancer is a common tumor of the endocrine system,and its pathogenesis has not been studied clearly.In recent years,studies on activator protein 1 (AP-1) and thyroid cancer have gradually increased.BRAF,RET,RAS,other gene mutations,cytokines,peptide hormones and other factors activate MAPK signaling pathway,promote transcription of Fos,Jun and other genes,and increase AP-1 expression.Over expression of AP-1 in thyroid cancer can activate downstream target genes such as VEGF,MMP-9,Cyclin D1,Fas,etc.,and play an crucial role in the process of proliferation,transformation,metastasis and apoptosis of thyroid cancer.This paper briefly reviews the progress of study between AP-1 and thyroid cancer.
作者
肖成
刘瑧
Xiao Cheng;Liu Zhen(Department of Pancreatic Endocrine Surgery,Shengjing Hospital Affiliated to China Medical University,Liaoning Shenyang 110000,China)
出处
《现代肿瘤医学》
CAS
2019年第6期1076-1079,共4页
Journal of Modern Oncology
基金
国家自然科学基金资助项目(编号:81672644)
作者简介
肖成(1993-),男,辽宁沈阳人,硕士研究生,主要从事甲状腺外科疾病诊治研究。E-mail:1016798469@qq.com;通讯作者:刘瑧(1973-),男,辽宁沈阳人,教授,主任医师,主要从事甲状腺癌、乳腺癌、胰腺癌基础与临床研究。E-mail:liuz@sj-hospital.org.
